



Notification of release of escrowed shares

Sydney, Australia, Tuesday, 10 September 2019: Next Science Limited ACN 622 382 549 (ASX:NXS) (**Next Science**), a global medical company with a unique platform of technologies to eliminate biofilms, advises, in accordance with Listing Rule 3.10A, that 71,528 fully paid ordinary shares in Next Science (**Escrowed Shares**) will be released from escrow on 25 September 2019.

The Escrowed Shares have been subject to an ASX imposed escrow restriction for a period of 12 months from their date of issue.

- - - END - - -

For further information, please contact:

Judith Mitchell, Managing Director
Phone: +61 2 8607 5124
Email: investorqueries@nextscience.com

Gillian Nairn, Company Secretary
Phone: +61 2 9375 7989
Email: investorqueries@nextscience.com

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and continued commercialisation of its proprietary Xbio™ technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology.

For further information visit: www.nextscience.com.